Naloxone Market, By Strength, By Route of Administration, By Distribution Channel, By Geography

PUBLISHED: March 19, 2024

PAGES: 199 Pages

DELIVERY TIME: 2-3 business days

ADD TO COMPARE

SELECT AN OPTION

Description

The naloxone market is estimated to be valued at USD 1,341.5 Mn in 2024 and is expected to reach USD 2,683.9 Mn by 2031, growing at a compound annual growth rate (CAGR) of 10.4% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2023/2024:	US$ 1,341.5 Mn
Historical Data for:	2019 To 2023	Forecast Period:	2024 to 2031
Forecast Period 2023/2024 to 2030/2031 CAGR:	10.40%	2030/2031 Value Projection:	US$ 2,683.9 Mn

Naloxone Market Share (%), By Region, 2024

Naloxone is an opioid antagonist used for the complete or partial reversal of opioid overdose. It works by competitively binding to opioid receptors and reversing and blocking the effects of other opiates. Naloxone has become an integral part of emergency medical treatment for opioid overdoses. With the ongoing opioid crisis in many parts of the world, the prevalence of opioid abuse has increased massively in recent times. As a result, the need for readily available naloxone formulations has grown for emergency treatment. This factor is expected to largely influence the growth trajectory of the global naloxone market in the coming years.

Market Dynamics:

The global naloxone market is primarily driven by the rising incidence of opioid overdose cases worldwide. According to the National Institute on Drug Abuse, opioid overdose mortality rates in the U.S. increased by over 130% between 2000 and 2019. Moreover, the COVID-19 pandemic further exacerbated the impact of social isolation on psychological health and increased opioid misuse in many countries. A high demand for user-friendly naloxone delivery formulations like nasal sprays and auto-injectors from both healthcare and law enforcement agencies is fueling the market growth. However, adverse side effects associated with naloxone therapy and the availability of alternative treatment options are limiting market expansion. Ongoing R&D into the development of long-acting naloxone formulations present lucrative opportunities for key players in the future.

Key Features of the Study:

This report provides an in-depth analysis of the global naloxone market, and provides market size (US$ MN) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global naloxone market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study includes EMERGENT, Indivior PLC, Akorn, Inc, Hikma Pharmaceuticals PLC, Viatris Inc., Sandoz, Teva Pharmaceuticals, Amphastar Pharmaceuticals, Inc., Kaleo, Inc., Pfizer Inc., Amneal Pharmaceuticals, Viatris Inc., Somerset Pharma, LLC, Orexo AB, and UCB Pharma.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global naloxone market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global naloxone market.

Market Segmentation

Strength:
- 2.0 mg/ml
- 1 mg/ml
- 0.4 mg/ml
- Others
Route of Administration:
- Intranasal
- Injectable
- Intramuscular
- Subcutaneous
- Intravenous
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- EMERGENT
- Indivior PLC
- Akorn, Inc
- Hikma Pharmaceuticals PLC
- Viatris Inc.
- Sandoz
- Teva Pharmaceuticals
- Amphastar Pharmaceuticals, Inc.
- Kaleo, Inc.
- Pfizer Inc.
- Amneal Pharmaceuticals
- Viatris Inc.
- Somerset Pharma, LLC
- Orexo AB
- UCB Pharma

Product Code: CMI1804

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Naloxone Market, By Strength
- Naloxone Market, By Route of Administration
- Naloxone Market, By Distribution Channel
- Naloxone Market, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Impact Analysis
Porter's Analysis
Industry Trends
Key Highlights
Epidemiology
Reimbursement Scenario
Regulatory Scenario
Product Launch and Approvals
Acquisition and Collaboration Scenario

4. Global Naloxone Market- Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Impact of COVID-19 on the Demand and Supply of Naloxone
Impact of COVID-19 on the Overall Healthcare Sector

5. Global Naloxone Market, By Strength, 2019-2031 (USD MN)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019-2031
- Segment Trends
2.0 mg/ml
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD MN)
1mg/ml
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD MN)
0.4 mg/ml
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD MN)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD MN)

6. Global Naloxone Market, By Route of Administration, 2019-2031 (USD MN)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019-2031
- Segment Trends
Intranasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD MN)
Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD MN)
Intramuscular
Subcutaneous
Intravenous

7. Global Naloxone Market, By Distribution Channel, 2019-2031 (USD MN)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019-2031
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD MN)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD MN)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD MN)

8. Global Naloxone Market, By Region, 2019-2031 (USD MN)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Regions, 2019-2031
- Regional Trends
North America
- Market Size and Forecast, By Strength, 2019-2031 (USD MN)
- Market Size and Forecast, By Route of Administration, 2019-2031 (USD MN)
- Market Size and Forecast, By Distribution Channel, 2019-2031 (USD MN)
- Market Size and Forecast, By Country, 2019-2031 (USD MN)
U.S.
Canada
Latin America
- Market Size and Forecast, By Strength, 2019-2031 (USD MN)
- Market Size and Forecast, By Route of Administration, 2019-2031 (USD MN)
- Market Size and Forecast, By Distribution Channel, 2019-2031 (USD MN)
- Market Size and Forecast, By Country, 2019-2031 (USD MN)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Market Size and Forecast, By Strength, 2019-2031 (USD MN)
- Market Size and Forecast, By Route of Administration, 2019-2031 (USD MN)
- Market Size and Forecast, By Distribution Channel, 2019-2031 (USD MN)
- Market Size and Forecast, By Country, 2019-2031 (USD MN)
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
- Market Size and Forecast, By Strength, 2019-2031 (USD MN)
- Market Size and Forecast, By Route of Administration, 2019-2031 (USD MN)
- Market Size and Forecast, By Distribution Channel, 2019-2031 (USD MN)
- Market Size and Forecast, By Country, 2019-2031 (USD MN)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Strength, 2019-2031 (USD MN)
- Market Size and Forecast, By Route of Administration, 2019-2031 (USD MN)
- Market Size and Forecast, By Distribution Channel, 2019-2031 (USD MN)
- Market Size and Forecast, By Country, 2019-2031 (USD MN)
GCC
Israel
Rest of Middle East
Africa
- Market Size and Forecast, By Strength, 2019-2031 (USD MN)
- Market Size and Forecast, By Route of Administration, 2019-2031 (USD MN)
- Market Size and Forecast, By Distribution Channel, 2019-2031 (USD MN)
- Market Size and Forecast, By Country/Region, 2019-2031 (USD MN)
South Africa
Central Africa
North Africa

9. Competitive Landscape

Company Profiles
- Viatris Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
- Opiant Pharmaceuticals
- Akorn Operating Company LLC
- Pfizer, Inc.
- Novartis AG
- Indivior Plc.
- Emergent BioSolutions Inc.
- Amphastar Pharmaceuticals, Inc.
- Kern Pharma, S.L.
- Hikma Pharmaceuticals PLC
- Mundipharma International Limited
- Kaleo, Inc.
- Pfizer Inc.
- Amneal Pharmaceuticals
- Viatris Inc.
- Somerset Pharma, LLC
- Orexo AB
- UCB Pharma